Rasha Aboelhassan: Even if we did not win today, the next generation will.
Rasha Aboelhassan, Senior Oncology Consultant at Nasser Institute Hospital, shared a post by
“The world cancer research day.
I work in cancer research,
because?
For the first thought about this question, I may say that the main reason is that: I like to find new chances of treatment for cancer patients every day which improves their survival and quality of life.
Although that this first thought is totally true,
But the second reason is that cancer treatment is the most challenging treatment in medicine and I love challenging.
when I give more deeper thinking about this question:
why do I love cancer research?
why do I love to work in cancer research and investigate new cancer therapy everyday?
I realise that I enjoy working against cancer it self,
Cancer is not a usual enemy, it do challenge itself every single day,
It gives resistance to each single weapon we discovered through the last decades.
Me as investigator, always love to go through cancer challenging and discover cancer new plans and weapons, uncover them, then fight and break cancer again.
I know that it’s a challenge
I know that I may get disappointed many times
but it’s not about who when the fight?
It’s about the journey, we as researchers like our journey of challenging, even if we did not win today, the next generation will.
we always win.”
Source: Rasha Aboelhassan/LinkedIn and National Cancer Institute (NCI)/LinkedIn
-
12:46 30/11/23 | BlogJohanna Joyce: the Flashlight method
-
12:31 30/11/23 | InsightJeff Ryckman: Omitting RT in bulky early-stage cHL
-
07:45 30/11/23 | BlogAaron Goodman: Hemoglobin Dissociation Curve! Good stuff
-
12:31 30/11Jeff Ryckman: Omitting RT in bulky early-stage cHL
-
17:28 29/11JeeSuk Chang: A multi-center trial - great efforts from the KROG team
-
17:00 29/11Maite Bourlon: Access to novel drugs for metastatic renal cell carcinoma is an unmet need in the Mexican population
-
23:17 28/11Manni Mohyuddin: Current trials must have observation/surveillance as control arm
-
23:04 28/11Juan P. Alderuccio: Our approach to secondary CNS involvement by aggressive lymphomas
-
17:43 28/11Michele Carbone: The world is full of good, honest, nice people
-
17:24 28/11Jessica Clerc: Celebrating 90 Years of Excellence and Dedication in Cancer Care!
-
17:44 25/11Carlos Pedraz: Congratulations, Dr. Rafael Rosell for the very well deserved 2023 ISLB Lifetime Achievement Award
-
17:10 25/11100 Influential Celebrities in Oncology: The 2023 Edition – Part 4
-
13:34 24/11"Bald for a Cause" initiative - UWC Dilijan College
-
17:34 28/11The International Association of Cancer Registries annual conference - IARC
-
18:05 26/11Submit your abstract by 13 February for ESMO-Breast-24 - ESMO
-
17:58 26/11Lisa A. Lacasse: My sincere gratitude to the ACS CAN team, our incredible volunteers, and supporters for another outstanding year
-
16:47 16/11How social determinants can influence a patient’s ability to stay in treatment - ASCO
-
13:22 16/11SIOP Europe Student Summer School for Paediatric Oncology
-
17:25 29/11NIH Director’s Early Independence Award supports junior scientists to launch independent careers - National Cancer Institute
-
17:07 29/11Santhosh Kumar Devadas: I’m starting a new position as a Professor of Medical Oncology and Chief of Bone Marrow Transplant at Ramaiah Memorial Hospital and Ramaiah Medical College
-
16:48 27/11CRCHD seeks motivated scientists to serve as Program Directors - NCI Disparities
-
16:25 27/11Luisa Basset completed a fruitful nine-year tenure on the CCI board of trustees - Childhood Cancer International
-
18:14 26/11Tristan Knight: Attention hematology / oncology and pediatric hematology / oncology fellows